Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications

Advanced Drug Delivery Reviews

Volumn 55, Issue 4, 2003, Pages 519-548

  Vauthier, Christine ^a   Dubernet, Catherine ^a   Fattal, Elias ^a   Pinto Alphandary, Huguette ^a   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Degradation; Nanoparticles; Poly(alkylcyanoacrylates); Polymerization; Therapeutic applications

Indexed keywords

BIODEGRADATION; DRUG THERAPY; NANOSTRUCTURED MATERIALS; TOXICITY;

BIOMEDICAL APPLICATIONS;

ORGANIC POLYMERS;

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CYANOACRYLATE DERIVATIVE; DIPEPTIDE; DOXORUBICIN; INSULIN; KYTORPHIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LOPERAMIDE; MONOMER; NANOCAPSULE; NANOPARTICLE; NEUROPEPTIDE; OLIGONUCLEOTIDE; PEPTIDE; POLY(CYANOACRYLATE); POLY(ISOBUTYLCYANOACRYLATE); POLY(ISOHEXYLCYANOACRYLATE); PROTEIN; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SAQUINAVIR; SOLVENT; TISSUE ADHESIVE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VACCINE;

BIODEGRADABILITY; BIOMEDICINE; BLOOD BRAIN BARRIER; CANCER; CANCER RESISTANCE; CYTOTOXICITY; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG INDICATION; EMULSION; EVAPORATION; IN VIVO STUDY; INFECTION; LISTERIOSIS; LYMPHATIC LEUKEMIA; NONHUMAN; POLYMERIZATION; PRECIPITATION; PRIORITY JOURNAL; REVIEW; SALMONELLOSIS; SYNTHESIS; TOXICITY;

EID: 0037466349     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00041-3     Document Type: Review

References (171)

1. Couvreur P., Kante B., Roland M., Guiot P., Bauduin P., Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31:1979;331-332.
2. Leonard F., Kulkarni R.K., Brandes G., Nelson J., Cameron J.J. Synthesis and degradation of poly(alkyl α-cyanoacrylates). J. Appl. Polym. Sci. 10:1996;259-272.
3. Skeist I., Miron J. Adhesive composition. Bikales N. Encyclopedia of Polymer Science and Engineering. Suppl. Vol. 2:1977;1-19 Wiley-Interscience, New York.
4. Coover H.W., Dreifus D.W., O'Connor J.T. Cyanoacrylate adhesives. Skeist I. Handbook of Adhesives. 3rd Edition: 1990;463-477 Van Nostrand Reinhold, New York.
5. King M.E., Kinney A.Y. Tissue adhesives: a new method of wound repair. Nurse Pract. 24:1999;66-73.
6. Oowaki H., Matsuda S., Sakai N., Ohta T., Iwata H., Sadato A., Taki W., Hashimoto N., Ikada Y. Non-adhesive cyanoacrylate as an embolic material for endovascular neurosurgery. Biomaterials. 21:2000;1039-1046.
7. Reece T.B., Maxey T.S., Kron I.L. A prospectus on tissue adhesives. Am. J. Surg. 182:2001;40S-44S.
8. Pollak J.S., White R.I. Jr. The use of cyanoacrylate adhesives in peripheral embolization. J. Vasc. Interv. Radiol. 12:2001;907-913.
9. De Jaeghere F., Doelker E., Gurny R. Nanoparticles. Mathiowitz E. The Encyclopedia of Controlled Drug Delivery. 1999;641-664 Wiley, New York.
10. Kumar N.M.V.R. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci. 3:2000;234-258.
11. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release. 70:2001;1-20.
12. Couvreur P., Barratt G., Fattal E., Legrand P., Vauthier C. Nanocapsule technology: a review. Crit. Rev. Drug Deliv. Syst. 19:2002;99-134.
13. Fattal E., Vauthier C. Nanoparticles as drug delivery systems. Swarbrick J., Boylan J.C. Encyclopedia of Pharmaceutical Technology. 2002;1874-1892 Marcel Dekker, New York.
14. Vauthier C., Couvreur P. Degradation of poly(alkylcyanoacrylates). Matsumara J.P., Steinbuchel A. Miscellaneous Biopolymers and Biodegradation of Synthetic Polymers. Handbook of Biopolymers. Vol. 9:2002;Wiley-VHC, New York. in press.
15. I. Brigger, C. Dubernet, P. Couvreur, Nanoparticles in cancer therapy and diagnosis, Adv. Drug Deliv. Rev. (in press).
16. Couvreur P., Kante B., Roland M. Les vecteurs lysosomotropes. J. Pharm. Belg. 35:1980;51-60.
17. Couvreur P., Kante B., Grislain L., Roland M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles. II. Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71:1982;790-792.
18. Barratt G., Couarraze G., Couvreur P., Dubernet C., Fattal E., Gref R., Labarre D., Legrand P., Ponchel G., Vauthier C. Polymeric micro and nanoparticles as drug carriers. Dumitriu S. Polymeric Biomaterials. 2nd Edition: 2001;753-782 Marcel Dekker, New York.
19. Kattan J., Droz J.P., Couvreur P., Marino J.P., Boutan-Laroze A., Rougier P., Brault P., Vranks H., Grognet J.M., Morge X., Sancho-Garnier H. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs. 10:1992;191-199.
20. Stella B., Arpicco S., Peracchia M.T., Desmaële D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89:2000;1452-1464.
21. Brigger I., Chaminade P., Marsaud V., Appel M., Besnard M., Gurny R., Renoir M., Couvreur P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 214:2001;37-42.
22. Calvo P., Gouritin B., Chacun H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J.P., Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18:2001;1157-1166.
23. Li Y.P., Pei Y.Y., Zhou Z.H., Zhang X.Y., Gu Z.H., Ding J., Zhou J.J., Gao X.J., Zhu J.H. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers: pharmacokinetics and anti-tumor effects. Biol. Pharm. Bull. 24:2001;662-665.
24. Pepper D.C. Anionic and zwitterionic polymerization of α-cyanoacrylates. J. Polym. Sci. Polym. Symp. 62:1978;65-77.
25. Ryan B., McCann G. Novel sub-ceiling temperature rapid depolymerization-repolymerization reactions of cyanoacrylate polymers. Macromol. Rapid Commun. 17:1996;217-227.
26. Hollock G.G. Expanded applications for octyl-2-cyanoacrylate as a tissue adhesive. Ann. Plast. Surg. 47:2001;576.
27. Marcovich R., Williams A.L., Rubin M.A., Wolf J.S. Comparison of 2-octyl cyanoacrylate adhesive, fibrin glue, and suturing for wound closure in the porcine urinary tract. Urology. 57:2001;806-810.
28. Kitoh A., Arima Y., Nishigori C., Kikuta K., Miyachi Y. Tissue adhesive and postoperative allergic meningitis. Lancet. 359:2002;1669-1670.
29. Burns D.T., Brown J.K., Dinsmore A., Harvey K. Base-activated latent fingerprints fumed with a cyanoacrylate monomer. A quantitative study using Fourrier-transformed infra-red spectroscopy. Anal. Chim. Acta. 362:1998;171-176.
30. Singer A.J., Quinn J.V., Clark R.E., Hollander J.E. Closure of lacerations and incision with octylcyanoacrylate: a multicenter randomized controlled trial. Surgery. 131:2002;270-276.
31. Bahsin D.K., Malhi N.J. Variceal bleeding and portal hypertension: much to learn, much to explore. Endoscopy. 34:2002;119-128.
32. Lescure F., Zimmer C., Roy D., Couvreur P. Optimization of polycyanoacrylate nanoparticle preparation: influence of sulfur dioxide and pH on nanoparticle characteristics. J. Colloid Interface Sci. 154:1992;77-86.
33. Douglas S.J., Illum L., Davis S.S. Particle size and size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers. J. Colloid Interface Sci. 103:1985;154-163.
34. Alonso M.J., Sanchez A., Torres D., Seijo B., Vila-Jato J.L. Joint effect of monomer and stabilizer concentrations on the physico-chemical characteristics of poly(butyl-2-cyanoacrylate) nanoparticles. J. Microencapsul. 7:1990;517-526.
35. Seijo B., Fattal E., Roblot-Treupel L., Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int. J. Pharm. 62:1990;1-7.
36. Boudad H., Legrand P., Lebas G., Cheron M., Duchêne D., Ponchel G.G. Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int. J. Pharm. 218:2001;113-124.
37. Gallardo M.M., Roblot-Treupel L., Mahuteau J., Genin I., Couvreur P., Plat M., Puisieux F. Nanocapsules et nanospheres d'alkylcyanoacrylate. Interaction principe actif-polymère. Proceedings of the 5th International Congress on Pharmaceutical Technology: 1989;36-45. Vol. 4.
38. Guise V., Drouin J.Y., Benoit J., Mahuteau J., Dumont P., Couvreur P. Vidarabine-loaded nanoparticles: a physicochemical study. Pharm. Res. 7:1990;736-741.
39. Grangier J.L., Puygrenier M., Gautier J.C., Couvreur P. Nanoparticles as carriers for growth hormone releasing factor. J. Control. Release. 15:1991;3-13.
40. Labib A., Lenaerts V., Chouinard F., Leroux J.C., Ouellet R., Van Lier J.E. Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm. Res. 8:1991;1027-1031.
41. Ghanem G.E., Joubran C., Arnould R., Lejeune F., Fruhling J. Labelled polycyanoacrylate nanoparticles for human in vivo use. Appl. Radiat. Isot. 44:1993;1219-1224.
42. Douglas S.J., Illum L., Davis S.S. Poly(butyl-2-cyanoacrylate) nanoparticles with differing surface charges. J. Control. Release. 3:1986;15-23.
43. Peracchia M.T., Vauthier C., Puisieux F., Couvreur P. Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol). J. Biomed. Mater. Res. 34:1997;317-326.
44. Peracchia M.T., Vauthier C., Popa M.I., Puisieux F., Couvreur P. Investigation of the formation of sterically stabilized poly(ethylene glycol/isobutylcyanoacrylate) nanoparticles by chemical grafting of polyethylene glycol during the polymerization of isobutyl cyanoacrylate. S.T.P. Pharma Sci. 7:1997;513-520.
45. Yang S.C., Ge H.X., Hu Y., Jiang X.Q., Yang C.Z. Formation of positively charged poly(butyl cyanoacrylate) nanoparticles stabilized by chitosan. Coll. Polym. Sci. 278:2000;285-292.
46. Al Khoury-Fallouh N., Roblot-Treupel L., Fessi H., Devissaguet J.P., Puisieux F. Development of a new process for the manufacture of poly(isobutylcyanoacrylate) nanocapsules. Int. J. Pharm. 28:1986;125-136.
47. Gasco M., Trotta M. Nanoparticles from microemulsions. Int. J. Pharm. 29:1986;267-268.
48. Vranckx H., Demoustier M., Deleers M. A new nanocapsule formulation with hydrophilic core: application to the oral administration of salmon calcitonin in rats. Eur. J. Pharm. Biopharm. 42:1996;345-347.
49. Lambert G., Fattal E., Pinto-Alphandary H., Gulik A., Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17:2000;707-714.
50. Watnasirichaikul S., Davies N.M., Rades R., Tucker I.G. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm. Res. 17:2000;684-689.
51. Gallardo M.M., Couarraze G., Denizot B., Treupel L., Couvreur P., Puisieux F. Preparation and purification of isohexylcyanoacrylate nanocapsules. Int. J. Pharm. 100:1993;55-64.
52. Aboubakar M., Puisieux F., Couvreur P., Deyme M., Vauthier C. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J. Biomed. Mater. Res. 47:1999;568-576.
53. Wohlgemuth M., Mächtle W., Mayer C. Improved preparation and physical studies of polybutylcyanoacrylate nanocapsules. J. Microencapsul. 17:2000;437-448.
54. Puglisi G., Fresta M., Giammona G., Venture C.A. Influence of the preparation conditions in poly(ethylcyanoacrylate) nanocapsules formation. Int. J. Pharm. 125:1995;283-287.
55. Fresta M., Cavallaro G., Giammona G., Wehrli E., Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials. 17:1996;751-758.
56. Damge C., Michel C., Aprahamian M., Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes. 37:1988;246-251.
57. Michel C., Aprahamian M., Defontaine L., Couvreur P., Damge C. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol. 43:1990;1-5.
58. Lowe P.J., Temple C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 46:1994;547-552.
59. Choi Y.K., Kim Y.H., Kim S.W. Block copolymer nanoparticles of ethylene oxide and isobutyl cyanoacrylate. Macromolecules. 28:1995;8419-8421.
60. Peracchia M.T., Desmaële D., Couvreur P., D'Angelo J. Synthesis of a novel poly(MePEG cyanoacrylate-co-alkylcyanoacrylate) amphiphilic copolymer for nanoparticle technology. Macromolecules. 30:1997;846-851.
61. Peracchia M.T., Desmaële D., Vauthier C., Labarre D., Fattal E., D'Angelo J., Couvreur P. Development of novel technologies for the synthesis of biodegradable pegylated nanoparticles. Gregoriadis G., McCormack B. Strategies for Stealth Therapeutic Systems. Targeting of Drugs. Vol. 6:1998;225-239 Plenum Press, New York.
62. Peracchia M.T., Vauthier C., Desmaële D., Gulik A., Dedieu J.C., Demoy M., D'Angelo J., Couvreur P. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res. 15:1998;548-554.
63. Peracchia M.T., Fattal E., Desmaele D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release. 60:1999;121-128.
64. Li Y.P., Pei Y.Y., Zhou Z.H., Zhang X.Y., Gu Z.H., Ding J., Zhou J.J., Gao X.J. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-α carrier. J. Control. Release. 71:2001;287-296.
65. Calvo P., Gouritin B., Brigger I., Lasmezas C., Deslys J., Williams A., Andreux J.P., Dormont D., Couvreur P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods. 111:2001;151-155.
66. Lenaerts V., Couvreur P., Christiaens-Leyh D., Joiris E., Roland M., Rollman B., Speiser P. Degradation of poly(isobutyl cyanoacrylate) nanoparticles. Biomaterials. 5:1984;65-68.
67. Vansnick L., Couvreur P., Christiaens-Ley D., Roland M. Molecular weights of free and drug-loaded nanoparticles. Pharm. Res. 1:1985;36-41.
68. Langer K., Seegmüller E., Zimmer A., Kreuter J. Characterization of polybutylcyanoacrylate nanoparticles: quantification of PBCA polymer and dextran. Int. J. Pharm. 110:1994;21-27.
69. Müller R.H., Lherm C., Herbort J., Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials. 11:1990;590-595.
70. Scherer D., Robinson J.R., Kreuter J. Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 101:1994;165-168.
71. Lherm C., Muller R., Puisieux F., Couvreur P. II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int. J. Pharm. 84:1992;13-22.
72. Wade C.W., Leonard F. Degradation of poly(methylcyanoacrylates). J. Biomed. Mater. Res. 6:1972;215-220.
73. Vezin W.R., Florence A.T. In vitro heterogenous degradation of poly(n-alkyl α-cyanoacrylates). J. Biomed. Mater. Res. 14:1980;93-106.
74. Vinters H.V., Ho H.W. Effects of isobutyl-2-cyanoacrylate polymer on cultured cells derived from murine cerebral microvessels. Toxicol. In Vitro. 2:1988;37-41.
75. Tseng Y.C., Hyon S.H., Ikada Y. Modification of the synthesis and investigation of properties for 2-cyanoacrylates. Biomaterials. 11:1990;73-79.
76. Cooper A.W., Harris P.J., Kumar G.K., Tebby J.C. Hydrolysis of alkylcyanoacrylate and ethoxycarbonylpropenoylphosphonate polymers. J. Polym. Sci. Part A: Polym. Chem. 27:1989;1967-1974.
77. Ley D., Couvreur P., Lenaerts V., Roland M., Speiser P. Etude du mécanisme de dégradation des nanoparticules de polycyanoacrylate d'alkyle. Labo Pharma-Probl. Tech. 32:1984;100-104.
78. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15:1983;335-345.
79. Lenaerts V., Nagelkerke J.F., Van Berkel T.J., Couvreur P., Grislain L., Roland M., Speiser P. In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Küpffer, endothelial, and parenchymal cells. J. Pharm. Sci. 73:1984;980-982.
80. Gibaud S., Andreux J.P., Weingarten C., Renard M., Couvreur P. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer. 6:1994;820-826.
81. Demoy M., Gibaud S., Andreux J.P., Weingarten C., Gouritin B., Couvreur P. Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm. Res. 14:1997;463-468.
82. Chavany C., Ledoan T., Couvreur P., Puisieux F., Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm. Res. 9:1992;441-449.
83. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 263:1994;1600-1603.
84. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84:1995;493-498.
85. Verdun C., Brasseur F., Vranckx H., Couvreur P., Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26:1990;13-18.
86. Chiannilkulchai N., Ammoury N., Caillou B., Devissaguet J.P., Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 26:1990;122-126.
87. Brasseur F., Verdun C., Couvreur P., Deckers C., Roland M. Evaluation expérimentale de l'efficacité thérapeutique de la doxorubicine associée associée aux nanoparticules de polyalkylcyanoacrylate. Proceeding of the 4th International Conference on Pharmaceutical Technology, Paris: 1986.
88. Fernandez-Urrusuno R., Fattal E., Rodrigues J.M. Jr., Feger J., Bedossa P., Couvreur P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res. 31:1996;401-408.
89. Ammoury N., Fessi H., Devissaguet J.P., Puisieux F., Benita S. Physicochemical characterization of polymeric nanocapsules and in vitro release of indomethacin as a drug model. S.T.P. Pharma. 5:1989;642-646.
90. Couvreur P., Vranckx H., Brasseur F., Roland M. Toxicité des nanoparticles à base de polycyanoacrylates d'alkyle. S.T.P. Pharma Sci. 5:1989;31-37.
91. Maassen S., Fattal E., Muller R., Couvreur P. Cell cultures for the assessment of toxicity and uptake of polymeric drug carriers. S.T.P. Pharma Sci. 3:1993;11-22.
92. Kante B., Couvreur P., Dubois-Krack G., De Meester C., Guiot P., Roland M., Mercier M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles. I. Free nanoparticles. J. Pharm. Sci. 71:1982;786-790.
93. Kreuter J., Wilson C.G., Fry J.R., Paterson P., Ratcliffe J.H. Toxicity and association of polycyanoacrylate nanoparticles with hepatocytes. J. Microencapsul. 1:1984;253-257.
94. Kubiak C., Couvreur P., Manil L., Clausse B. Increased cytotoxicity of nanoparticle-carried adriamycin in vitro and potentiation by verapamil and amiodarone. Biomaterials. 10:1989;553-556.
95. Gipps E., Groscurt P., Kreuter J., Speiser P.P. The effects of poly(alkylcynoacrylate) nanoparticles on human normal and malignant mesenchymal cells in vitro. Int. J. Pharm. 40:1987;23-31.
96. Gaspar R., Preat V., Opperdoes F.R., Roland M. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm. Res. 9:1992;782-787.
97. Fernandez-Urrusuno R., Fattal E., Porquet D., Feger J., Couvreur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol. Appl. Pharmacol. 130:1995;272-279.
98. Fernandez-Urrusuno R., Fattal E., Féger J., Couvreur P., Théron P. Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials. 18:1997;511-517.
99. Couvreur P., Tulkens P., Roland M., Trouet A., Speiser P. Nanocapsules: a new lysosomotropic carrier. FEBS Lett. 84:1977;323-326.
100. Guise V., Jaffray P., Delattre J., Puisieux F., Adolphe M., Couvreur P. Comparative cell uptake of propidium iodide associated with liposomes or nanoparticles. Cell. Mol. Biol. 33:1987;397-405.
101. Fattal E., Youssef M., Couvreur P., Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob. Agents Chemother. 33:1989;1540-1543.
102. Youssef M., Fattal E., Alonso M.J., Roblot-Treupel L., Sauzieres J., Tancrede C., Omnes A., Couvreur P., Andremont A. Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice. Antimicrob. Agents Chemother. 32:1988;1204-1207.
103. Forestier F., Gerrier P., Chaumard C., Quero A.M., Couvreur P., Labarre C. Effect of nanoparticle-bound ampicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages. J. Antimicrob. Chemother. 30:1992;173-179.
104. Balland O., Pinto-Alphandary H., Pecquet S., Andremont A., Couvreur P. The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. J. Antimicrob. Chemother. 33:1994;509-522.
105. Pinto-Alphandary H., Balland O., Laurent M., Andremont A., Puisieux F., Couvreur P. Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharm. Res. 11:1994;38-46.
106. Buchmeier N.A., Heffron F. Inhibition of macrophage phagosome-lysosome fusion by Salmonella typhimurium. Infect. Immun. 59:1991;2232-2238.
107. Page-Clisson M.E., Pinto-Alphandary H., Chachaty E., Couvreur P., Andremont A. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm. Res. 15:1998;544-549.
108. Gaspar R., Opperdoes F.R., Preat V., Roland M. Drug targeting with polyalkylcyanoacrylate nanoparticles - in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86:1992;782-787.
109. Fouarge M., Dewulf M., Couvreur P., Roland M., Vranckx H. Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis. J. Microencapsul. 6:1989;29-34.
110. Chiannilkulchai N., Driouich Z., Benoit J.P., Parodi A.L., Couvreur P. Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther. 5:1989;1-11.
111. Couvreur P., Grislain L., Lenaerts V., Brasseur F., Guiot P., Biornacki A. Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. Guiot P., Couvreur P. Polymeric Nanoparticles and Microparticles. 1986;27-93 CRC Press, Boca Raton, FL.
112. Daemen T., Hofstede G., Ten Kate M.T., Bakker-Woudenberg I.A., Scherphof G.L. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer. 61:1995;716-721.
113. Gibaud S., Rousseau C., Weingarten C., Favier R., Douay L., Andreux J.P., Couvreur P. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J. Control. Release. 52:1998;131-139.
114. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 316:1985;820-823.
115. Treupel L., Poupon M.F., Couvreur P., Puisieux F. Vectorisation of doxorubicin in nanospheres and reversion of pleiotropic resistance of tumor cells. C.R. Acad. Sci. III. 313:1991;171-174.
116. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44:1992;509-517.
117. Bennis S., Chapey C., Couvreur P., Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur. J. Cancer. 1:1994;89-93.
118. Nemati F., Dubernet C., Colin de Verdière A., Poupon M.F., Treupel Acar L., Puisieux F., Couvreur P. Some parameters influencing cytotoxicity of free doxorubicin loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of particles per cell. Int. J. Pharm. 102:1994;55-62.
119. Colin de Verdiere A., Dubernet C., Nemati F., Poupon M.F., Puisieux F., Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 33:1994;504-508.
120. Colin de Verdiere A., Dubernet C., Nemati F., Soma E., Appel M., Ferte J., Bernard S., Puisieux F., Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer. 76:1997;198-205.
121. Pepin X., Attali L., Domrault C., Gallet S., Metreau J.M., Reault Y., Cardot P.J., Imalalen M., Dubernet C., Soma E., Couvreur P. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B. 702:1997;181-191.
122. Soma C.E., Dubernet C., Barratt G., Nemati F., Appel M., Benita S., Couvreur P. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm. Res. 16:1999;1710-1716.
123. Soma C.E., Dubernet C., Barratt G., Benita S., Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Release. 68:2000;283-289.
124. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods: A Companion to Methods in Enzymology. 18:1999;286-295.
125. Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., Helene C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11:1994;1370-1378.
126. Nakada Y., Fattal E., Foulquier M., Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm. Res. 13:1996;38-43.
127. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA. 91:1994;10460-10464.
128. Lambert G., Fattal E., Brehier A., Feger J., Couvreur P. Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. Biochimie. 80:1998;969-976.
129. Lambert G., Fattal E., Pinto-Alphandary H., Gulik A., Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int. J. Pharm. 214:2001;13-16.
130. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C., Auclair C., Couvreur P. EWS fli-1 antisense nanocapsules inhibit Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279:2000;401-406.
131. Tanaka K., Iwakuma T., Harimaya K., Sato H., Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99:1997;239-247.
132. Stein C.A. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Biotechnology. 14:1996;47-149.
133. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47:2001;65-81.
134. Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:1995;171-174.
135. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:1997;325-328.
136. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15:1998;67-74.
137. Friese A., Seiller E., Quack G., Lorenz B., Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49:2000;103-109.
138. Sopala M., Schweizer S., Schafer N., Nurnberg E., Kreuter J., Seiller E., Danysz W. Neuroprotective activity of a nanoparticulate formulation of the glycine B site antagonist MRZ 2/576 in transient focal ischaemia in rats. Arzneimittelforschung. 52:2002;168-174.
139. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16:1999;1564-1569.
140. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski B., Zanella F.E., Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126:2002;131-141.
141. Ramge P., Unger R.E., Oltrogge J.B., Zenker D., Begley D., Kreuter J., Von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci. 12:2000;1931-1940.
142. Alyaudtin R.N., Reichel A., Lobenberg R., Ramge P., Kreuter J., Begley D.J. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target. 9:2001;209-221.
143. Araujo L., Lobenberg R., Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J. Drug Target. 6:1999;373-385.
144. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16:1999;1836-1842.
145. Calvo P., Gouritin B., Villarroya H., Eclancher F., Giannavola C., Klein C., Andreux J.P., Couvreur P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 15:2002;1317-1326.
146. Jani P., Halbert G.W., Langridge J., Florence A.T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41:1989;809-812.
147. Le Fevre H.E., Joel D.D., Shidlousky G. Retention of ingested latex particles in Peyers patches of gerinfree and conventional mice. Soc. Exp. Biol. Med. 179:1985;522-528.
148. Damge C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. Nanocapsules as carriers for oral peptide delivery. J. Control. Release. 13:1990;233-239.
149. Florence A.T., Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev. 50:2001;S69-S89.
150. Kreuter J., Muller V., Munz K. Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int. J. Pharm. 55:1989;39-45.
151. Aprahamian M., Michel C., Humbert W., Devissaguet J.P., Damge C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol. Cell. 61:1987;69-76.
152. Aboubakar M., Couvreur P., Pinto-Alphandary H., Gouritin B., Lacour B., Farinotti R., Puisieux F., Vauthier C. Insulin-loaded nanocapsules for oral administration: in vitro and in vivo investigation. Drug Deliv. Res. 49:2000;109-117.
153. Damge C., Vranckx H., Balschmidt P., Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86:1997;1403-1409.
154. Watnasirichaikul S., Rades T., Tucker I.G., Davies N.M. In-vitro release and oral bioavailability in diabetic rats of insulin using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54:2002;473-480.
155. Damge C., Vonderscher J., Marbach P., Pinget M. Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J. Pharm. Pharmacol. 49:1997;949-954.
156. Torres-Lugo M., Peppas N.A. Transmucosal delivery systems for calcitonin: a review. Biomaterials. 21:2000;1191-1196.
157. O'Hagan D.T., Palin K., Davis S.S. Poly(butyl-2-cyanoacrylate) particles as adjuvant for oral immunization. Vaccine. 7:1989;213-216.
158. Ponchel G., Touchard F., Duchene D., Peppas N.A. Bioadhesive analysis of the controlled-release systems. III. Fracture and interpenetration analysis in poly(acrylic acid) containing systems. J. Control. Release. 5:1987;129-141.
159. Ponchel G., Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34:1998;191-219.
160. Takeuchi H., Yamamoto H., Kawashima Y.Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47:2001;39-54.
161. Pimienta C., Chouinard F., Labib A., Lenaerts V. Effect of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow. Int. J. Pharm. 80:1992;1-8.
162. Lenaerts V., Couvreur P., Grislain L., Maincent P. Nanoparticles as a gastrointestinal drug delivery system. Lenaerts V., Gurny R. Bioadhesive Drug Delivery Systems. 1990;94-104 CRC Press, Boca Raton, FL.
163. Maincent P., Le Verge R., Sado P., Couvreur P., Devissaguet J.P. Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J. Pharm. Sci. 75:1986;955-958.
164. Damge C., Aprahamian M., Balboni G., Hoeltzel A., Andrieu V., Devissaguet J.P. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int. J. Pharm. 36:1987;121-125.
165. Hubert B., Atkinson J., Guerret M., Hoffman M., Devissaguet J.P., Maincent P. The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm. Res. 8:1991;734-738.
166. Boudad H., Legrand P., Coconnier M.H., Appel M., Duchene D., Ponchel G. Absorption of saquinavir from combined hydroxypropyl b cyclodextrin and poly(alkylcyanoacrylate) nanoparticles through CACO-2 cells monolayers. Proceedings of the 4th World Meeting on Pharmaceutics Biopharmaceutics Pharmaceutical Technology, Florence, Italy, 8-11 April: 2001;1385-1386.
167. Gautier J.C., Grangier J.L., Barbier A., Dupont P., Dussosoy D., Pastor G., Couvreur P. Biodegradable nanoparticles for subcutaneous administration of growth hormone releasing factor (hGRF). J. Control. Release. 3:1992;205-210.
168. Zimmer A., Kreuter J., Robinson J.R. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J. Microencapsul. 8:1991;497-504.
169. Le Bourlais C.A., Chevanne F., Turlin B., Acar L., Zia H., Sado P.A., Needham T.E., Leverge R. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study. J. Microencapsul. 14:1997;457-467.
170. Desai S.D., Blanchard J. Pluronic F127-based ocular delivery systems containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. J. Deliv. Target. Ther. Agents. 7:2000;201-207.
171. Fresta M., Fontana G., Bucolo C., Cavallaro G., Giammona G., Puglisi G. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanospheres-encapsulated acyclovir. J. Pharm. Sci. 90:2001;288-297.